Tony Newitt's Plasma Treatment Recovery
Analysis based on 7 articles · First reported Jun 12, 2026 · Last updated Jun 13, 2026
The successful recovery of Tony Newitt due to plasma treatment highlights the critical role of plasma-derived medicines. This event could increase public awareness and potentially boost plasma donations, positively impacting companies involved in blood and plasma collection, processing, and the production of immunoglobulin medicines. The United Kingdom's reliance on imported plasma also suggests potential investment opportunities in domestic plasma collection and manufacturing to achieve greater self-sufficiency.
Tony Newitt, a 71-year-old cancer survivor, was paralyzed from the neck down by Guillain-Barre Syndrome in March 2025. After being told he might never walk again, he underwent life-saving intravenous immunoglobulin (IVIG) and therapeutic plasma exchange treatments, both derived from donated plasma, at University Hospitals Coventry and Warwickshire NHS Trust. Within days, his symptoms stabilized, and after extensive physiotherapy, he proudly walked out of Leamington Rehabilitation Hospital in October. Tony Newitt and his daughter, Laurence Marshall, are now urging more people to donate plasma, calling it 'liquid gold.' United Kingdom — NHS Blood and Transplant reports that over 3,200 patients have received UK-donated plasma medicines since March, five years after a ban due to mad cow disease concerns was lifted. The United Kingdom currently meets 23% of its NHS immunoglobulin demand, relying heavily on imports from the United States, and United Kingdom — NHS Blood and Transplant aims to increase this to 35% by 2030.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard